ORCHESTRA BIOMED HOLDINGS IN (OBIO) Fundamental Analysis & Valuation

NASDAQ:OBIO • US68572M1062

4.38 USD
-0.22 (-4.78%)
At close: Mar 12, 2026
4.39 USD
+0.01 (+0.23%)
Pre-Market: 3/13/2026, 4:20:59 AM
Overview Stock Chart Technical Analysis Fundamental Analysis Forecast Earnings Financials Ownership News

This OBIO fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

Fundamental Rating

2

OBIO gets a fundamental rating of 2 out of 10. The analysis compared the fundamentals against 184 industry peers in the Health Care Equipment & Supplies industry. Both the profitability and financial health of OBIO have multiple concerns. OBIO does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

1

1. OBIO Profitability Analysis

1.1 Basic Checks

  • In the past year OBIO has reported negative net income.
  • In the past year OBIO has reported a negative cash flow from operations.
  • OBIO had negative earnings in each of the past 5 years.
  • In the past 5 years OBIO always reported negative operating cash flow.
OBIO Yearly Net Income VS EBIT VS OCF VS FCFOBIO Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2020 2021 2022 2023 2024 -20M -40M -60M

1.2 Ratios

  • With a Return On Assets value of -71.66%, OBIO is not doing good in the industry: 73.91% of the companies in the same industry are doing better.
  • OBIO's Return On Equity of -171.70% is on the low side compared to the rest of the industry. OBIO is outperformed by 71.74% of its industry peers.
Industry RankSector Rank
ROA -71.66%
ROE -171.7%
ROIC N/A
ROA(3y)-56.32%
ROA(5y)-79.02%
ROE(3y)-108.38%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
OBIO Yearly ROA, ROE, ROICOBIO Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2020 2021 2022 2023 2024 0 -500 -1K

1.3 Margins

  • With an excellent Gross Margin value of 93.01%, OBIO belongs to the best of the industry, outperforming 98.91% of the companies in the same industry.
  • OBIO's Gross Margin has declined in the last couple of years.
  • The Profit Margin and Operating Margin are not available for OBIO so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 93.01%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-9.78%
GM growth 5YN/A
OBIO Yearly Profit, Operating, Gross MarginsOBIO Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2020 2021 2022 2023 2024 0 1K -1K 2K -2K

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

3

2. OBIO Health Analysis

2.1 Basic Checks

  • OBIO does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • OBIO has more shares outstanding than it did 1 year ago.
  • Compared to 1 year ago, OBIO has a worse debt to assets ratio.
OBIO Yearly Shares OutstandingOBIO Yearly Shares OutstandingYearly Shares Outstanding 2020 2021 2022 2023 2024 10M 20M 30M
OBIO Yearly Total Debt VS Total AssetsOBIO Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2020 2021 2022 2023 2024 20M 40M 60M 80M

2.2 Solvency

  • OBIO has an Altman-Z score of -3.96. This is a bad value and indicates that OBIO is not financially healthy and even has some risk of bankruptcy.
  • With a Altman-Z score value of -3.96, OBIO is not doing good in the industry: 68.48% of the companies in the same industry are doing better.
  • A Debt/Equity ratio of 0.32 indicates that OBIO is not too dependend on debt financing.
  • OBIO has a Debt to Equity ratio (0.32) which is comparable to the rest of the industry.
Industry RankSector Rank
Debt/Equity 0.32
Debt/FCF N/A
Altman-Z -3.96
ROIC/WACCN/A
WACC9.97%
OBIO Yearly LT Debt VS Equity VS FCFOBIO Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2020 2021 2022 2023 2024 0 20M -20M 40M -40M 60M

2.3 Liquidity

  • A Current Ratio of 4.73 indicates that OBIO has no problem at all paying its short term obligations.
  • OBIO has a better Current ratio (4.73) than 72.83% of its industry peers.
  • A Quick Ratio of 4.72 indicates that OBIO has no problem at all paying its short term obligations.
  • With a decent Quick ratio value of 4.72, OBIO is doing good in the industry, outperforming 79.35% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 4.73
Quick Ratio 4.72
OBIO Yearly Current Assets VS Current LiabilitesOBIO Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2020 2021 2022 2023 2024 20M 40M 60M 80M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

3

3. OBIO Growth Analysis

3.1 Past

  • The earnings per share for OBIO have decreased strongly by -12.42% in the last year.
  • OBIO shows a small growth in Revenue. In the last year, the Revenue has grown by 6.46%.
EPS 1Y (TTM)-12.42%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%2.44%
Revenue 1Y (TTM)6.46%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%-12.77%

3.2 Future

  • Based on estimates for the next years, OBIO will show a quite strong growth in Earnings Per Share. The EPS will grow by 13.50% on average per year.
  • The Revenue is expected to grow by 74.50% on average over the next years. This is a very strong growth
EPS Next Y-7.43%
EPS Next 2Y0.96%
EPS Next 3Y6.84%
EPS Next 5Y13.5%
Revenue Next Year6.59%
Revenue Next 2Y4.43%
Revenue Next 3Y-6%
Revenue Next 5Y74.5%

3.3 Evolution

OBIO Yearly Revenue VS EstimatesOBIO Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033 0 50M 100M 150M 200M 250M
OBIO Yearly EPS VS EstimatesOBIO Yearly EPS VS EstimatesYearly EPS VS Estimates 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033 0 -2 -4 -6 -8

More info and screens

Find the best growth stocksShow best growing peers

0

4. OBIO Valuation Analysis

4.1 Price/Earnings Ratio

  • OBIO reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
  • Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for OBIO. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
OBIO Price Earnings VS Forward Price EarningsOBIO Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
OBIO Per share dataOBIO EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 -0.5 -1 -1.5

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y0.96%
EPS Next 3Y6.84%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. OBIO Dividend Analysis

5.1 Amount

  • OBIO does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

OBIO Fundamentals: All Metrics, Ratios and Statistics

ORCHESTRA BIOMED HOLDINGS IN

NASDAQ:OBIO (3/12/2026, 8:02:16 PM)

Premarket: 4.39 +0.01 (+0.23%)

4.38

-0.22 (-4.78%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)11-10
Earnings (Next)04-01
Inst Owners29.89%
Inst Owner Change-4.66%
Ins Owners4.85%
Ins Owner Change16.36%
Market Cap247.29M
Revenue(TTM)2.82M
Net Income(TTM)-75.10M
Analysts81.43
Price Target13.7 (212.79%)
Short Float %1.92%
Short Ratio3.79
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)6.25%
Min EPS beat(2)2.68%
Max EPS beat(2)9.82%
EPS beat(4)4
Avg EPS beat(4)4.05%
Min EPS beat(4)0.13%
Max EPS beat(4)9.82%
EPS beat(8)7
Avg EPS beat(8)2.55%
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)2
Avg Revenue beat(2)14.62%
Min Revenue beat(2)11.42%
Max Revenue beat(2)17.83%
Revenue beat(4)3
Avg Revenue beat(4)5.09%
Min Revenue beat(4)-70.51%
Max Revenue beat(4)61.63%
Revenue beat(8)4
Avg Revenue beat(8)-7.94%
Revenue beat(12)6
Avg Revenue beat(12)-2.62%
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0.71%
EPS NQ rev (1m)0%
EPS NQ rev (3m)2.38%
EPS NY rev (1m)0%
EPS NY rev (3m)0.21%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)5.73%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0.17%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 87.76
P/FCF N/A
P/OCF N/A
P/B 5.65
P/tB 5.65
EV/EBITDA N/A
EPS(TTM)-1.81
EYN/A
EPS(NY)-1.63
Fwd EYN/A
FCF(TTM)-1.09
FCFYN/A
OCF(TTM)-1.07
OCFYN/A
SpS0.05
BVpS0.77
TBVpS0.77
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -71.66%
ROE -171.7%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 93.01%
FCFM N/A
ROA(3y)-56.32%
ROA(5y)-79.02%
ROE(3y)-108.38%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-9.78%
GM growth 5YN/A
F-Score4
Asset Turnover0.03
Health
Industry RankSector Rank
Debt/Equity 0.32
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 353.8%
Cap/Sales 41.31%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 4.73
Quick Ratio 4.72
Altman-Z -3.96
F-Score4
WACC9.97%
ROIC/WACCN/A
Cap/Depr(3y)194.88%
Cap/Depr(5y)224.07%
Cap/Sales(3y)17.77%
Cap/Sales(5y)19.48%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-12.42%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%2.44%
EPS Next Y-7.43%
EPS Next 2Y0.96%
EPS Next 3Y6.84%
EPS Next 5Y13.5%
Revenue 1Y (TTM)6.46%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%-12.77%
Revenue Next Year6.59%
Revenue Next 2Y4.43%
Revenue Next 3Y-6%
Revenue Next 5Y74.5%
EBIT growth 1Y-25.18%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-15.49%
EBIT Next 3Y-4.45%
EBIT Next 5Y4.75%
FCF growth 1Y-39.47%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-37.23%
OCF growth 3YN/A
OCF growth 5YN/A

ORCHESTRA BIOMED HOLDINGS IN / OBIO FAQ

Can you provide the ChartMill fundamental rating for ORCHESTRA BIOMED HOLDINGS IN?

ChartMill assigns a fundamental rating of 2 / 10 to OBIO.


Can you provide the valuation status for ORCHESTRA BIOMED HOLDINGS IN?

ChartMill assigns a valuation rating of 0 / 10 to ORCHESTRA BIOMED HOLDINGS IN (OBIO). This can be considered as Overvalued.


Can you provide the profitability details for ORCHESTRA BIOMED HOLDINGS IN?

ORCHESTRA BIOMED HOLDINGS IN (OBIO) has a profitability rating of 1 / 10.


Can you provide the financial health for OBIO stock?

The financial health rating of ORCHESTRA BIOMED HOLDINGS IN (OBIO) is 3 / 10.